Karyopharm Therapeutics (KPTI) Stock Statistics & Valuation Metrics

Karyopharm Therapeutics has a market cap or net worth of $231.16M. The enterprise value is $353.06M.

Karyopharm Therapeutics has 22,662,943 shares outstanding. The number of shares has decreased by -2.65% in one year.

Karyopharm Therapeutics’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -236.62%.

The current PE Ratio of Karyopharm Therapeutics is ―. Karyopharm Therapeutics’s PEG ratio is -0.00453.

In the last 12 months, Karyopharm Therapeutics had revenue of 146.07M and earned -196.04M in profits. Earnings per share was -17.93.

In the last 12 months, operating cash flow was -59.11M and capital expenditures 0.00, giving a free cash flow of -59.11M billion.

Karyopharm Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Karyopharm Therapeutics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).

Karyopharm Therapeutics as a current ratio of 1.12, with Debt / Equity ratio of -86.91%

In the past 12 months, Karyopharm Therapeutics has paid 43.00K in taxes.

Karyopharm Therapeutics EV to EBITDA ratio is -1.69, with an EV/FCF ratio of -3.36.

Karyopharm Therapeutics has $90.85M in cash and marketable securities with $230.87M in debt, giving a net cash position of -$140.02M billion.

Gross margin is 96.03%, with operating margin of -62.10%, and net profit margin of -134.21%.

The average price target for Karyopharm Therapeutics is $13.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy